195 related articles for article (PubMed ID: 16733229)
1. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
2. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
4. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
5. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
6. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
Toblli JE; Cao G; Casas G; Mazza ON
Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
[TBL] [Abstract][Full Text] [Related]
10. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol.
Parenti A; Filippi S; Amerini S; Granger HJ; Fazzini A; Ledda F
J Pharmacol Exp Ther; 2000 Feb; 292(2):698-703. PubMed ID: 10640308
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
Prisant LM
J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
[TBL] [Abstract][Full Text] [Related]
13. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
14. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
[TBL] [Abstract][Full Text] [Related]
15. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
Greven J; Gabriëls G
Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
Münzel T; Gori T
J Am Coll Cardiol; 2009 Oct; 54(16):1491-9. PubMed ID: 19815121
[TBL] [Abstract][Full Text] [Related]
17. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.
Broeders MA; Doevendans PA; Bekkers BC; Bronsaer R; van Gorsel E; Heemskerk JW; Egbrink MG; van Breda E; Reneman RS; van Der Zee R
Circulation; 2000 Aug; 102(6):677-84. PubMed ID: 10931809
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Pharmacology; 2008; 81(2):110-7. PubMed ID: 17952013
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
20. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM
Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
